KDR and telomere syndrome: Multi-target tyrosine kinase inhibitors (MTKIs) such as pazopanib, a standard second- or third-line agent for metastatic STS acting via vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) inhibition, are widely used.